×

Chimeric Therapeutics Limited

Chimeric Therapeutics is developing ground-breaking CAR T cell therapies for solid tumors based on research at the City of Hope Cancer Centre in Los Angeles. The technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor targeting component of the CAR to reprogram T cells and is currently undergoing Phase 1 clinical trials at City of Hope in glioblastoma.

Spotlight Videos

Stocks of the Hour: PainChek, Chimeric Therapeutics, Torque Metals

A snapshot of the stocks on the move, featuring PainChek (ASX:PCK), Chimeric Therapeutics (ASX:CHM) and Torque Metals (ASX:TOR).

WATCH VIDEO
All Chimeric Therapeutics Limited Content

News